CY1116168T1 - Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 - Google Patents

Συγκρυσταλλοι και αλατα αναστολεων toy ccr3

Info

Publication number
CY1116168T1
CY1116168T1 CY20151100331T CY151100331T CY1116168T1 CY 1116168 T1 CY1116168 T1 CY 1116168T1 CY 20151100331 T CY20151100331 T CY 20151100331T CY 151100331 T CY151100331 T CY 151100331T CY 1116168 T1 CY1116168 T1 CY 1116168T1
Authority
CY
Cyprus
Prior art keywords
ccr3
hypercellulators
toy
salt salts
salts
Prior art date
Application number
CY20151100331T
Other languages
English (en)
Inventor
Markus Frank
Hans Haeberle
Manuel Henry
Thorsten Pachur
Marco Santagostino
Uwe Stertz
Thomas Trebing
Ulrike Werthmann
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1116168T1 publication Critical patent/CY1116168T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά συγκρυστάλλους και άλατα αναστολέων του CCR3 του τύπου (1), φαρμακευτικές συνθέσεις, οι οποίες περιέχουν αυτά και μεθόδους χρήσης αυτών ως μέσων για την αντιμετώπιση και/ή την πρόληψη νόσων που σχετίζονται με τον υποδοχέα CCR3.
CY20151100331T 2010-10-07 2015-04-07 Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 CY1116168T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186901 2010-10-07
EP11764572.1A EP2625174B1 (en) 2010-10-07 2011-10-06 Co-crystals and salts of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
CY1116168T1 true CY1116168T1 (el) 2017-02-08

Family

ID=44741339

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100331T CY1116168T1 (el) 2010-10-07 2015-04-07 Συγκρυσταλλοι και αλατα αναστολεων toy ccr3

Country Status (36)

Country Link
US (3) US8742115B2 (el)
EP (1) EP2625174B1 (el)
JP (1) JP5794713B2 (el)
KR (3) KR102163874B1 (el)
CN (1) CN103140486B (el)
AP (1) AP3268A (el)
AR (1) AR083353A1 (el)
AU (1) AU2011311530B2 (el)
BR (2) BR112013008211B1 (el)
CA (1) CA2807255C (el)
CL (1) CL2013000488A1 (el)
CO (1) CO6710910A2 (el)
CY (1) CY1116168T1 (el)
DK (1) DK2625174T3 (el)
EA (1) EA029097B1 (el)
EC (1) ECSP13012600A (el)
ES (1) ES2535264T3 (el)
GE (1) GEP20166488B (el)
HR (1) HRP20150419T1 (el)
HU (1) HUE024540T2 (el)
IL (1) IL224269A (el)
MA (1) MA34545B1 (el)
ME (1) ME02040B (el)
MX (1) MX2013003785A (el)
MY (1) MY167898A (el)
NZ (1) NZ605827A (el)
PE (1) PE20140188A1 (el)
PL (1) PL2625174T3 (el)
PT (1) PT2625174E (el)
RS (1) RS53858B1 (el)
SG (1) SG188949A1 (el)
SI (1) SI2625174T1 (el)
TW (1) TWI546294B (el)
UA (1) UA109290C2 (el)
UY (1) UY33655A (el)
WO (1) WO2012045803A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2018187503A1 (en) * 2017-04-05 2018-10-11 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
ES2950453T3 (es) 2017-04-05 2023-10-10 Alkahest Inc Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
KR20200067859A (ko) * 2017-10-13 2020-06-12 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물
WO2019222265A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2002501052A (ja) 1998-01-21 2002-01-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法
AU2654399A (en) 1998-02-02 1999-08-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CA2467555A1 (en) 2001-11-29 2003-08-14 Schering Corporation Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
CA2514092C (en) 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
CN1871222A (zh) 2003-10-24 2006-11-29 霍夫曼-拉罗奇有限公司 Ccr3受体拮抗剂
DE602005013931D1 (el) 2004-02-05 2009-05-28 Schering Corp
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP2059515A2 (en) 2006-04-12 2009-05-20 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
BRPI0710512A2 (pt) 2006-04-20 2012-06-05 Hoffmann La Roche moduladores derivados de diazepan de receptores de quimiocinas
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
AP3268A (en) 2015-05-31
KR20130118313A (ko) 2013-10-29
NZ605827A (en) 2015-09-25
AP2013006679A0 (en) 2013-01-31
MY167898A (en) 2018-09-26
GEP20166488B (en) 2016-06-10
BR112013008211A2 (pt) 2016-06-21
BR112013008211A8 (pt) 2017-10-10
KR102239690B1 (ko) 2021-04-13
EA029097B1 (ru) 2018-02-28
AU2011311530B2 (en) 2015-04-09
IL224269A (en) 2017-08-31
PT2625174E (pt) 2015-03-09
KR20190104645A (ko) 2019-09-10
UY33655A (es) 2012-04-30
US20120264729A1 (en) 2012-10-18
AR083353A1 (es) 2013-02-21
EP2625174B1 (en) 2015-01-21
AU2011311530A1 (en) 2013-01-31
RS53858B1 (en) 2015-08-31
ECSP13012600A (es) 2013-07-31
US8742115B2 (en) 2014-06-03
PL2625174T3 (pl) 2015-06-30
TW201305134A (zh) 2013-02-01
ES2535264T3 (es) 2015-05-07
KR102163874B1 (ko) 2020-10-12
KR20180005717A (ko) 2018-01-16
HRP20150419T1 (hr) 2015-05-22
CA2807255A1 (en) 2012-04-12
EA201300436A8 (ru) 2018-01-31
CA2807255C (en) 2018-11-13
MA34545B1 (fr) 2013-09-02
EP2625174A1 (en) 2013-08-14
SI2625174T1 (sl) 2015-03-31
WO2012045803A1 (en) 2012-04-12
TWI546294B (zh) 2016-08-21
KR101844215B1 (ko) 2018-04-03
US20140135307A1 (en) 2014-05-15
BR112013008211B1 (pt) 2021-08-24
CN103140486A (zh) 2013-06-05
DK2625174T3 (da) 2015-02-02
CL2013000488A1 (es) 2013-07-05
JP2013542207A (ja) 2013-11-21
JP5794713B2 (ja) 2015-10-14
MX2013003785A (es) 2013-06-05
SG188949A1 (en) 2013-05-31
UA109290C2 (uk) 2015-08-10
ME02040B (me) 2015-05-20
EA201300436A1 (ru) 2013-08-30
CN103140486B (zh) 2016-08-03
BR122021010665B1 (pt) 2022-03-15
US20150105371A1 (en) 2015-04-16
PE20140188A1 (es) 2014-02-26
HUE024540T2 (hu) 2016-01-28
CO6710910A2 (es) 2013-07-15
US9233950B2 (en) 2016-01-12

Similar Documents

Publication Publication Date Title
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CY1119422T1 (el) Παραγωγα μπετουλινης
CY1119533T1 (el) Νεοι θεραπευτικοι παραγοντες
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
EA201201648A1 (ru) Стимуляторы sgc
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
PE20151994A1 (es) Modificador del sabor dulce
CY1111269T1 (el) Ρυθμιστες βενζιμιδαζολης του vr1
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
CY1113240T1 (el) Αλατα ενωσεων αναστολεα hiv
EA201591957A1 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CY1124419T1 (el) Συνθεσεις προφαρμακων φουμαρικου μονομεθυλεστερα